News

2024.01 - Announcement of successfully securing funding from the plan "New Generation Lithuania" which is financed under the European Union economic recovery and resilience facility instrument NextGenerationEU

Title / Nr. 10-036-T-0004:
Implementation of the Feetsee project assessed by the European Horizon Programme, EIC Accelerator

Objective:
The aim of the project is to develop and market a new and innovative product “Feetsee” for the prevention of diabetic foot complications, “Feetsee”, within the framework of the European Horizon Programme, EIC Accelerator, which has not been funded by the European Commission, but has been awarded the EC’s Quality Label.The implementation of the envisaged activities will create the conditions for the development of a science-intensive business sector in Lithuania and will increase Lithuania’s visibility and networking in the international scientific space. The applicant will obtain an EU registration certificate and prepare for the market launch of a high added value product, thus creating jobs and profits.

Project value:
3239340 €

EU financing:
2267500 €

Project duration:
December 2023 – April 2026

 

NKL iliustracija (horizontali)

2023.02 - Feetsee by Diabetis receives the Lithuanian-American Innovation Award 2022!

The Baltic-American Freedom Foundation, U.S. Embassy in Vilnius, and Innovation Agency Lithuania celebrate visionaries of Lithuania’s tech and entrepreneurial community and the cutting-edge technologies created in partnership with entities from the U.S.
We are very humbled and deeply honored by this recognition!

2023.02 - The National Science Foundation’s Center webinar is kicking off

The National Science Foundation’s Center to Stream Healthcare in Place (http://C2SHiP.org) webinar on Feetsee technology is kicking off! Excited to see Dr. David Armstrong and other experts in the field!
Click to join https://lnkd.in/ddU2qZAf

2023.02 - Feetsee was presented to the Brad Hazzard MP, Australian Minister for Health

Feetsee was presented to the Honourable Brad Hazzard MP, Australian Minister for Health at DMZ.
While in Toronto, it was inspiring to see such solid interest in Diabetic Foot Ulcer management from Canadian and Australian government representatives, venture capital firms, and healthcare system stakeholders.

2023.01 - Winners of the Next Big Idea contest have arrived to Toronto

Winners of the Next Big Idea contest have arrived to Toronto – well, most of them, life sometimes throws you a curveball – and started their program at DMZ. Can’t wait to see how much these talented hashtag#Lithuanian entrepreneurs, Urtė Steikūnienė, Simonas Stankus, Justinas Balčiūnas, Vytenis (WeTennis) Pakenas will benefit from is and can help their respective companies Diabetis JSC, Inbalance grid, Ligence and isLucid grow in North America!
We wish Viezo Donat Ponamariov, Caszyme Monika Paule, PhD and UVIRESO – Ultraviolet irradiation engineering solutions were also here with us – we will continue to support you!

2023.01 - Feetsee is proud to join the Next Big Idea accelerator!

The results are in! Pace Global Advantage and DMZ have chosen seven well-deserving Lithuanian companies as the winners of The Next Big Idea Contest! The founders of each of these chosen companies will come to Toronto, Canada to engage in workshops, programme led sessions and one-on-one meetings with tenured industry experts. During their time in Toronto, winners will gain knowledge of Canada’s tech environment, funding options, legal landscapes, HR practices and receive advice on how to build their company in North America. The seven winning companies include isLucid, UVIRESO – Ultraviolet irradiation engineering solutions, Feetsee, Inbalance grid, Caszyme, Viezo and Ligence. Congratulations to each of the winners! Follow the link to learn more about each of these winning companies.

2022.05 - Feetsee team joined the Malvern Diabetic Foot Conference 2022.

Feetsee team joined the Malvern Diabetic Foot Conference 2022. This event is the longest standing biennial international diabetic foot meeting, and this year gathered a full house of experts!

2022.04 - Feetsee is now FDA-registered

Feetsee is now an FDA-registered Class medical device designed for people living with diabetes and neuropathy. The Feetsee device measures the temperature of the feet for signs of inflammation. Temperature monitoring is a proven way to help reduce the number of diabetic foot ulcers in multiple clinical studies over the past 20 years.

• Feetsee has his presence in the US, incorporated the US entity,
• Feetsee is now an FDA-registered Class I medical device designed for people living with diabetes and neuropathy
• Feetsee launched a Series A financing round with two US-based investment entities as co-leads

2021.11 - Feetsee Algorithm presented at Global Meeting on Diabetes and Endocrinology in Dubai

Our team’s endocrinology expert will present the Feetsee Algorithm for Automated Foot Detection in Thermal and Optical Images for Temperature Asymmetry Analysis during the upcoming Global Meeting on Diabetes and Endocrinology in Dubai. This is an international event for doctors and researchers across the world.